Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galapagos NV (GLPG)

Galapagos NV (GLPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,468,890
  • Shares Outstanding, K 54,820
  • Annual Sales, $ 375,370 K
  • Annual Income, $ -34,550 K
  • 60-Month Beta 1.58
  • Price/Sales 31.46
  • Price/Cash Flow N/A
  • Price/Book 4.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.29
  • Number of Estimates 5
  • High Estimate 0.28
  • Low Estimate -0.90
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -185.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
182.07 +14.91%
on 11/15/19
217.29 -3.72%
on 12/10/19
+17.86 (+9.33%)
since 11/13/19
3-Month
144.05 +45.23%
on 10/02/19
217.29 -3.72%
on 12/10/19
+48.05 (+29.82%)
since 09/13/19
52-Week
85.00 +146.13%
on 12/27/18
217.29 -3.72%
on 12/10/19
+101.71 (+94.61%)
since 12/13/18

Most Recent Stories

More News
Galapagos completes recruitment of NOVESA trial in systemic sclerosis

Mechelen, Belgium; 5 December 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690.

GLPG : 209.21 (-2.94%)
Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 25 November 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.

GLPG : 209.21 (-2.94%)
Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 18 November 2019; 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP.

GLPG : 209.21 (-2.94%)
Transparency notification - Gilead holds 25.10% of Galapagos shares

Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

-- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional...

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

-- Data Demonstrate Efficacy and Safety Across a Wide Range of Patient Populations, Including Those Intolerant or Unresponsive to Biologic Treatment --

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
Galapagos increases share capital through warrant exercise by Gilead

Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from a warrant exercise by Gilead.

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

Mechelen, Belgium; 1 November 2019; 21:01 CET - Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD), delivered an exercise notice to Galapagos NV (Euronext &...

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that new data from across the companies' inflammatory disease research and development program will be presented...

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)
GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases

GLPG : 209.21 (-2.94%)
GILD : 65.77 (-2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade GLPG with:

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

2nd Resistance Point 214.35
1st Resistance Point 211.78
Last Price 209.21
1st Support Level 207.00
2nd Support Level 204.79

See More

52-Week High 217.29
Last Price 209.21
Fibonacci 61.8% 166.76
Fibonacci 50% 151.14
Fibonacci 38.2% 135.53
52-Week Low 85.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar